Action GMAB GENMAB A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Genmab A/S

Actions

GMAB

DK0010272202

Marché Fermé - Nasdaq Copenhagen
Autres places de cotation
 16:59:31 31/05/2024 		Varia. 5j. Varia. 1 janv.
1 937 DKK +0,31 % Graphique intraday de Genmab A/S +0,55 % -10,12 %
21/05 Genmab A/S réaffirme ses prévisions financières pour 2024 CI
21/05 Genmab A/S (CPSE:GMAB) a finalisé l'acquisition de ProfoundBio, Inc. CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Genmab A/S : Investigational Acasunlimab (DuoBody® PD L1x4 1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non small Cell Lung Cancer (mNSCLC)
PU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BU
Transactions in Connection with Share Buy-back Program
GL
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
BU
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Genmab Completes Acquisition of ProfoundBio
BU
Genmab Completes Acquisition of ProfoundBio
GL
Transactions in Connection with Share Buy-back Program
GL
Legal Limbo: Genmab's Ofatumumab SPC Dilemma Heads To CJEU
AQ
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
BU
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
GL
Transactions in Connection with Share Buy-back Program
GL
Genmab A/S : has published its Articles of Association
PU
Genmab A/S : Articles of association dated May 07, 2024 – English
PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise
GL
Transactions in Connection with Share Buy-back Program
GL
Genmab A/S : Investor Presentation - May 2024
PU
Genmab A/S : Interim Report for the First Quarter of 2024
PU
Genmab A/S : First Quarter 2024 Financial Results Presentation
PU
Genmab Announces Financial Results for the First Quarter of 2024
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action GMAB
  4. Actualités Genmab A/S
  5. Communiqués
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT